169 related articles for article (PubMed ID: 37971500)
1. Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene.
Song X; Zhang Y; Lv X; Xu Z; Long Y; Gai Y; Jiang D; Lei P; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):965-977. PubMed ID: 37971500
[TBL] [Abstract][Full Text] [Related]
2. Construction of truncated PSMA as a PET reporter gene for CAR T cell trafficking.
Zhang Y; Song X; Xu Z; Lv X; Long Y; Lan X; Lei P
J Leukoc Biol; 2024 Feb; 115(3):476-482. PubMed ID: 37943840
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
[TBL] [Abstract][Full Text] [Related]
6. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
7. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
8. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
9.
Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
11. Preclinical assessment of
Mandiwana V; Kalombo L; Lemmer Y; Labuschagne P; Semete-Makokotlela B; Sathekge M; Ebenhan T; Zeevaart JR
J Labelled Comp Radiopharm; 2019 Jun; 62(7):332-345. PubMed ID: 31054157
[TBL] [Abstract][Full Text] [Related]
12. PET imaging of new target CDK19 in prostate cancer.
Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
[TBL] [Abstract][Full Text] [Related]
13.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
14. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
15. Diverse PSMA expression in primary prostate cancer: reason for negative [
Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of
Albisinni S; Artigas C; Aoun F; Biaou I; Grosman J; Gil T; Hawaux E; Limani K; Otte FX; Peltier A; Sideris S; Sirtaine N; Flamen P; van Velthoven R
BJU Int; 2017 Aug; 120(2):197-203. PubMed ID: 27981732
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
18. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
[TBL] [Abstract][Full Text] [Related]
19. Detection and localisation of primary prostate cancer using
Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography in intermediate and high risk prostate cancer.
El Hajj A; Yacoub B; Mansour M; Khauli R; Bulbul M; Nassif S; Haidar MB
Medicine (Baltimore); 2019 Nov; 98(44):e17491. PubMed ID: 31689752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
